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Abstract Studies were performed to develop a sub-lOO nm 
biodegradable colloidal system for the efficient delivery of drugs 
and diagnostic agents to the lymphatic system. Nanospheres of 
poly(lactide-co-glycolide) were prepared by interfacial polymer 
deposition. The nanospheres were coated with block co-polymers 
in order to modify their surface characteristics. Radiolabelling of 
the nanospheres for in vivo tracing was achieved by the 
incorporation of the lipophilic complex 111 In-oxine during 
nanosphere preparation. In vitro stability of the radiolabelled 
nanospheres was determined in rat serum at 37°C. The lymphatic 
distribution of the nanospheres was determined after subcuta-
neous administration to the rat. Lymphatic uptake of all coated 
systems was enhanced compared to the uncoated nanospheres, 
and a maximal uptake of 17% of the administered dose in the 
regional lymph nodes was achieved. These observations suggest 
that the nanospheres are suitable for diagnostic and therapeutic 
applications in clinical and experimental medicine. 
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1. Introduction 
The uptake of colloidal drug delivery systems from an in-
terstitial site into the lymphatic system is governed by the 
physicochemical characteristics of the colloid and the patho-
physiological structure of the interstitial space and lymphatic 
system [1], A colloid, administered interstitially, for lymphatic 
targeting purposes should drain well from the site of injection 
and be well retained in the regional lymph nodes. The concept 
of surface modification, wherein model polystyrene nano-
spheres have been coated with block co-polymers that provide 
a sterically stabilised surface, has been used previously to 
control the rate of drainage from a subcutaneous injection 
site and to manipulate the lymphatic distribution [2]. 
Targeting of nanospheres to specific body sites for the de-
livery of therapeutic agents to man requires that the delivery 
system is both biocompatible and biodegradable [3], Lipo-
somes have been investigated extensively by other workers 
for lymphatic delivery but with disappointing results: 6.3% 
of the administered dose represented total lymph node uptake 
[4], More recently, liposomes incorporating a PEG 1900 Da 
layer have been investigated following s,c, administration to 
mice [5]. Maximum reported levels in the lymph nodes were 
approximately 250 cpm/mg tissue normalised to 106 cpm of 
radio label injected per mouse after 48 h. Due to such poor 
lymphatic delivery of liposomes, poly(lactide-co-glycolide) 
(PLGA) was chosen in the present work as a suitable biode-
gradable polymer for the investigation of nanosphere prepara-
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tion and biodistribution. Nanospheres were radio labelled by 
the incorporation of 111 Indium-oxine and their surface mod-
ified by coating with adsorbed block co-polymers. The block 
co-polymers were poloxamers and poloxamines from series 
with a constant length of polypropylene oxide chains and 
increasing chain length of polyethylene oxide. The serum sta-
bility of the radiolabel was also determined. 
2. Materials and methods 
PolY(DL-lactide-co-glycolide 75:25) (Res orner RG755) of average 
molecular weight 50000 was obtained from Boehringer Ingelheim 
(Germany). The poloxamines 901, 904 and 908 and the poloxamers 
401,402,403, and 407 were a gift from BASF (USA). Their composi-
tion and molecular weight characteristics are given in Table 1. 
m Indium-oxine was purchased from Amersham International (UK) 
as a solution in HEPES buffer at a pH of 6.5-7.5, with a specific 
activity of 37 MBq/ml. All other chemicals were of analytical grade 
and used as obtained. 
Nanospheres were prepared by modification of a method described 
previously [6]. PLGA was dissolved in 10 ml acetone to a concentra-
tion of 0.1 % w/v, and 3 MBq of the m In-oxine added. This organic 
phase was then added dropwise to 20 ml of de-ionised water during 
magnetic stirring. After evaporation of the organic phase, the result-
ing nanospheres were concentrated by ultrafiltration (Amicon Inc., 
USA) to 0.2% w/v. Particles were then coated by incubation overnight 
in a 0.2% w/v solution of the various block co-polymers at room 
temperature. Excess polymer and radio label were subsequently re-
moved by passage of the nanospheres through a 10 cm column of 
Sepharose CL-4B (Pharmacia, Sweden). 
The particle size of the resultant nanospheres was determined by 
photon correlation spectroscopy (PCS) using a Malvern 4700 instru-
ment (Malvern, UK). The adsorbed layer thickness of the coating 
layer was determined from the difference in radii of coated and un-
coated systems. The zeta potential of the nanospheres was determined 
by laser doppler anemometry using a Malvern Zetasizer IV (Malvern, 
UK) in 10 mM McIlvaine buffer at pH 7. 
To determine the stability of the radiolabel, nanospheres, cleaned of 
excess radiolabel and polymer, were incubated at 3rC in 50% v/v rat 
serum over a time course of 6 h. Samples (0.5 ml) were collected in 
duplicate at selected times of 5 min, I, 3, and 6 h and were passed 
down columns of sepharose CL-4B (Pharmacia, Sweden) using PBS at 
pH 7.4, (Sigma, UK), as eluent to separate the dissociated radiolabel 
from the nanospheres. Twenty-five consecutive fractions of 0.5 ml 
were collected and counted for associated radioactivity in a gamma 
counter (LKB 1282 Compugamma CS, LKB, Finland). The stability 
was expressed as the percentage of activity remaining associated with 
the nanospheres. The total activity applied to the column was taken to 
be the denominator for the calculations. 
Nanospheres prepared without radiolabel were incubated overnight 
at room temperature with free radio label and then cleaned of excess 
radiolabel. These nanospheres were then incubated with serum in the 
same manner as above. In this way any association of the radiolabel 
to the nanosphere surface could be determined and the stability of 
surface bound radiolabel monitored. 
The biodistribution of the free radio label and the various labelled 
PLGA nanosphere systems was determined in groups of three male 
Wistar rats, body weight 150 ± 109. Biodistribution of free radiolabel 
was determined either alone or when co-administered with naked 
nanospheres (0.1 mg), poloxamine 908 (0.1%), or a combination of 
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nanospheres and poloxamine 908. All systems were injected subcuta-
neously (I 00 ~I) into the dorsal surface of the left hind footpad, under 
halothane anaesthesia. After 6 h (2, 6 and 24 h for uncoated PLGA 
nanospheres), a blood sample was taken from the tail vein and the 
rats killed by cervical dislocation under halothane anaesthesia. Asso-
ciated radioactivity was measured in the footpad (injection site), the 
regional lymph nodes (popliteal, inguinal, iliac and renal nodes) as 
defined by Hebel and Stromberg [7], and the organs of the reticuloen-
dothelial system. Total blood volume was calculated assuming that 
blood in the rat represented 7.5% v/w of body weight [8,9]. 
3. Results and discussion 
Particle size, as determined by PCS, showed that the nano-
spheres of PLGA were in the sub-IOO nm range with a low 
polydispersity index (Table 2). The adsorbed layer thickness 
of the poloxamers and poloxamines on the surface of the 
nanospheres was related to the number of polyethylene oxide 
(PEO) units in their structures. An increase in thickness was 
found for an increased number of PEO units in the co-poly-
mer chain. Poloxamines 901, 904, and 908 contain 4, 15 and 
119 PEO units, respectively, per PEO chain, whereas they all 
share a common anchoring polypropylene oxide (PPO) chain 
of 68 PPO units. The related series of poloxamers each share a 
common anchoring chain of 69 PPO units with 5, 11, 20 and 
98 PEO units per PEO chain for poloxamers 401, 402, 403 
and 407, respectively (Table I). Since the adsorbed layers 
measured were small in comparison to the standard deviation 
of the size measurements, confirmation of nanosphere coating 
was obtained by measuring the surface potential of the nano-
spheres (Table 2). A general reduction in zeta potential was 
observed when the nanospheres were coated with the block 
co-polymers. This is attributed to the masking of the inherent 
negative charge of the nanospheres (carboxyl groups in the 
polymer end groups [10]). The PEO chains bring about a shift 
in the shear plane to a distance further from the nanosphere 
surface [11]. 
In order to determine the in vivo distribution of the nano-
spheres, an associated radio label should be well retained un-
der physiological conditions. After an initial burst release of 
surface associated radio label from the nanospheres, the in 
vitro release should be minimal or stop [12]. The PLGA nano-
spheres with surface adsorbed label exhibited a rapid initial 
burst release resulting in only 60% of the radioactivity remain-
ing associated with the nanospheres after 5 min (Fig. I). 
Thereafter, there was a continued loss of radiolabel from 
the nanosphere surface with time, such that after 6 h only 
around 35% of the label remained with the nanospheres. 
This dissociation of label from the nanosphere surface was 
unaffected by the presence of a coating polymer. 
Table 1 
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Fig. 1. Stability of III Indium radio labelled nanospheres. 
Nanospheres, labelled by the incorporation of the label into 
the nanosphere structure during preparation, also exhibited a 
rapid burst release of the radio label after 5 min (Fig. I), 
probably as a result of dissociation of surface bound radio-
label. However, further loss of the radio label was less pro-
nounced with only a further 14% of the label being lost 
from the nanospheres over the following 6 h. Thus, around 
50% of the activity remained associated with the nanospheres 
at this time whether the nanospheres were uncoated or coated 
with poloxamine 908. This figure was similar after 6 hours 
incubation with serum. A slow release of 111 In-oxine from 
PLGA nanospheres, after an initial burst, has been observed 
previously [12] and has been attributed to the slow leaching of 
the radiolabel from the porous nanosphere structure. The 
porous nature of the nanospheres has also been suggested as 
a factor that allows the access of biological fluids into the 
nanosphere core [13]. 
Nanospheres were radiolabelled by the incorporation of the 
lipophilic, gamma emitting complex 111 In-oxine during nano-
sphere preparation. The method was developed by Scholes 
[14] following unsuccessful attempts to label the nanospheres 
by surface labelling with 125Iodine or incorporation of 
125Iodine cholesteryl aniline or neutron activation following 
incorporation of samarium acetylacetonate. The conclusion 
from this work was that of these only 111 In-oxine could be 
employed for radiolabelling of PLGA nanospheres prepared 
by the polymer interfacial deposition technique. 
Other workers [15] have radio labelled poly(lactic acid) using 
14C, in which the radiolabelled PLA was synthesised from D,L-
lactic acid [carbonyl 14C]. Nanospheres were then prepared by 
a precipitation method. The radiolabel was reported to be 
released and excreted as carbon dioxide from the lungs only 
after degradation of the nanospheres. However, the ideal 
radiolabel for ease of detection would be a gamma emitter. 
Composition and molecular weight characteristics of poloxamers 401, 402, 403 and 407 and poloxamines 901, 904 and 908 
Polymer Molecular weight % Ethylene oxide Number of PPO units per chain" Number of PEO units per chaina 
Poloxamers 
401 4400 10 69 5 
402 5000 20 69 11 
403 5750 30 69 20 
407 12600 70 69 98 
Poloxamines 
901 4700 10 17 4 
904 6700 40 17 15 
908 25000 80 17 119 
'Poloxamines contain four chains of both PEO and PPO; poloxamers have two PEO chains but only one PPO. 
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Table 2 
Characterisation of PLGA nanospheres (n = 6) 
Polymer Mean size (nm) Mean polydispersity 
Uncoated 
Poloxamers 
401 
402 
403 
407 
Poloxamines 
901 
904 
908 
8S.1 ± 3.2 
88.S ± 1.6 
87.0 ± 2.2 
87.7 ± 2.7 
84.1 ±2.4 
flocculation 
88.6±2.1 
9S.2± 3.2 
O.lS4 ± 0.034 
0.126 ± 0.038 
0.127 ± 0.030 
0.146 ± 0.042 
0.122 ± 0.OS2 
0.128±0.0IS 
0.12S ± O.03S 
PLGA has been radiolabelled using 111 Indium which was che-
lated with diethylenetriamine pentaacetic acid stearyl amide 
(DTPA-SA) [16]. Serum stability studies showed less than a 
2% loss of label during 4 h. However, the nanospheres were 
prepared by an emulsification method and replication of the 
results using the polymer interfacial deposition technique 
herein have proved unsuccessful. 
Free 111 In-oxine, administered in aqueous solution, was 
rapidly drained from the injection site, with only 14% of the 
administered dose remaining after 6 h (Table 3). The label was 
seen to pass through the lymphatics to the bloodstream with 
insignificant uptake by the lymph nodes. Since only 50% of 
the administered dose was recovered, it can be assumed that 
the remainder had been excreted in both the urine and faeces 
[17]. 
Free label co-administered with naked PLGA nanospheres 
exhibited a reduced rate of clearance from the injection site 
with 41% of the administered dose remaining in the footpad 
after 6 hours (Table 3). It is thus evident that some of the free 
label had become associated with the nanospheres; the results 
reflecting uptake of nanospheres as well as distribution of free 
label. The lymph node uptake of the label was higher than for 
the free label alone, with 3% of the dose sequestered by the 
nodes. Levels of activity in the blood and liver were compar-
able to free label alone. The recovery levels for this system 
were much higher than for the free label, indicating that the 
label associated with the nanospheres was not so rapidly ex-
creted. 
Free label co-administered with an aqueous solution of po-
loxamine 908 exhibited a distribution profile comparable to 
free label alone, indicating that there was no association be-
tween the free poloxamine and the free label. When free label 
was co-administered with both PLGA nanospheres and po-
loxamine 908, the levels of administered dose observed at the 
injection site were around 30%, which is greater than for free 
label alone, but less than for free label administered with 
naked PLGA nanospheres. This may be due to a reduced 
association of the label with the nanospheres as a result of 
Table 3 
Adsorbed layer thickness (nm) 
J.7 
1.0 
1.3 
4.S 
1.8 
S.I 
321 
Mean zeta potential (mV) 
-3S.9±2.0 
-12.7±0.9 
-14.9 ± 1.6 
-IS.3± 1.3 
-7.4± 1.4 
-IS.4±2.2 
-S.7±1.4 
the steric barrier created by the adsorption of poloxamine 908 
to the nanosphere surface, or may be a reflection of the in-
creased drainage of poloxamine coated nanospheres if the 
label is associated with the nanosphere surface. 
Naked PLGA nanospheres, with incorporated label, were 
seen to be retarded at the injection site for long periods of 
time. Even 24 hours after administration, 65% of the adminis-
tered dose was retained in the footpad (Table 4). Since colloid 
passage through the interstitium to the initial lymphatics is 
facilitated by aqueous channels [18], it is not surprising that 
the nanosphere movement was inhibited, considering the hy-
drophobicity of the PLGA nanospheres. Previous work has 
investigated the mechanism of uptake of colloids from the 
interstitium into the initial lymphatics [2,19,20]. Two path-
ways of colloid transport were proposed, one being via extra-
cellular dispersed particle flow directly into the initiallympha-
tic vessels, and the other by intracellular carriage after 
phagocytosis by macrophages within the interstitium. Nano-
spheres which do drain into the lymphatic system are effec-
tively sequestered by the regional lymph nodes, with the ma-
jority of lymphatic uptake in the primary, popliteal node. The 
phagocytic cells of the subcapsular sinus of the cortex and the 
classical macrophages of the medulla in both the popliteal and 
iliac nodes are mainly responsible for the phagocytosis of 
nanospheres [2]. Any nanospheres which are then not seques-
tered by the lymph node macrophages and reach the general 
circulation can be removed by the Kupffer cells of the liver. 
The coating of the naked nanospheres with block co-poly-
mers of the poloxamer or poloxamine series resulted in an 
enhanced drainage from the injection site compared to un-
coated nanospheres (Table 5). It is believed that the surface 
of the nanospheres was more acceptable for passage through 
the aqueous channels of the interstitium. Therefore, a greater 
number of nanospheres were presented to the macrophages of 
the lymph nodes. If the nanosphere surface was recognisable 
to the macrophages as foreign then the nanosphere would be 
retained. However, nanospheres with a sufficient steric barrier 
to prevent opsonisation with plasma proteins and minimise 
The biodistribution of free III In-oxine 6 h after s.c. administration into the rat hind footpad 
System Injection site Total lymph nodes Liver 
Free III In-oxine 14.1 ± 3.1 1.0 ± 0.2 4.2 ± O.S 
Co-administered with: 
PLGA nanospheres 
Poloxamine 908 
N anospheres+ P908 
41.2 ± 2.9 
IS.2±2.7 
29.0±4.4 
Data are expressed as % of initial dose (n = 3). 
3.3 ± 1.1 
0.9 ± 0.1 
6.9±0.S 
4.2±0.6 
S.4 ± 0.4 
8.6 ± J.7 
Blood Recovery 
I I.S ± 2.0 S1.3 ± 8.S 
18.S ± S.6 92.3±9.2 
16.3 ± 3.8 62.9±7.3 
11.6 ± 2.8 76.S ± 10.4 
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Table 4 
The biodistribution of naked PLGA nanospheres, 2, 6 or 24 h after s.c. administration 
Time (h) Injection site Total lymph nodes Liver Blood Recovery 
2 73.9±7.1 2.4±0.3 0.3±O.l 3.7 ± 0.5 
3.7 ± 0.5 
2.8 ± 0.4 
82.8 ± 7.0 
82.7± 5.6 
87.2 ± 6.0 
6 67.9±5.9 3.0±0.4 1.0±0.1 
24 65.9 ± 5.0 4.9 ± 1.0 2.5 ± 0.4 
Data are expressed as % of initial dose (n == 3). 
cell-nanosphere interaction [21] should escape recognition by 
the lymph node macrophages and enter the general circula-
tion. All coated systems exhibited an enhanced lymph node 
uptake compared to naked uncoated nanospheres. Increased 
hydrophilicity of the nanospheres, as reflected in the increased 
PEO content of the coating polymer, did not result in large 
differences in injection site drainage but did result in an in-
crease in lymphatic uptake; the maximum uptake was around 
11 % of the administered dose for poloxamer 407 and 17% for 
poloxamine 90S by the lymph nodes (Fig. 2). The popliteal 
node was responsible for the greatest uptake by the lymph 
nodes in each case. 
The coating of polystyrene nanospheres (60 nm) with the 
same block co-polymers has been reported previously [2]. In 
these experiments there was a greater drainage from the in-
jection site with increasing hydrophilicity. High lymph node 
accumulation was demonstrated for nanospheres coated with 
block co-polymers possessing intermediate PEO chain lengths 
such as poloxamine 904. A greater degree of block co-polymer 
hydrophilicity was required for the poloxamers and polox-
amines adsorbed to PLGA nanospheres. This may be a result 
of the PLGA nanospheres being larger in size, but is more 
likely to be due to smaller adsorbed layer thicknesses of the 
block co-polymers on the nanospheres, resulting in greater 
hydrophobicity. For example, poloxamine 90S produced a 
layer of 9.6 nm on polystyrene nanospheres compared to 
only 5.1 nm on PLGA nanospheres. The masking of negative 
surface charge of the nanospheres and the hydrophobic 
PLGA core is, therefore, less effective (zeta potential of po-
loxamine 90S on polystyrene was -1.S mV compared to -5.7 
mV for PLGA). 
It is noted that the initial burst release of III In-oxine from 
the nanospheres will result in a biodistribution profile which is 
not totally representative of the nanospheres alone. Since free 
label remains at the injection site to some degree (14%), the 
injection site values for the PLGA nanosphere systems may be 
slightly overestimated. Conversely, free radio label is not taken 
up by the lymph node macrophages and thus the loss of 
radio label will result in an underestimation of the lymph 
node uptake for the nanosphere systems. Moreover, the re-
sults are considered to be well indicative of a situation where 
Table 5 
an incorporated 'drug' is being delivered to the regional nodes 
for therapeutic effect. Free radiolabel (,drug') does not accu-
mulate in the lymph node macrophages. In contrast, radio-
label (,drug') detected in the lymph nodes after dissection 
must have been delivered there by the nartospheres. It is 
also possible, but considered unlikely, that the nanospheres. 
empty of label (,drug') could have then passed through to the 
circulation. 
The results herein are presented in terms of percentage up-
take of the administered dose. Other workers in this field 
often express the results in terms of percentage uptake per 
gram of tissue. The average weight of a popliteal lymph 
node is around 12 mg. For poloxamine 90S coated PLGA 
nanospheres, the uptake by the popliteal lymph node was 
10% of the administered dose. This equates to 1000%/g. For 
the iliac node, 4.6% of the administered dose was taken up. 
Taking the weight of this node to be 13 mg, then the uptake 
equates to 354%/g. Other workers, investigating the lymphatic 
uptake of a lymphotrophic polyglucosylated macrocomplex 
following intravenous administration, report 35-45%/g in the 
central lymph nodes of rats [22]. Accumulation of ultrasmall 
superparamagnetic iron oxide (USIOP) particles in the lymph 
nodes has also been reported, with 3.6%/g in the mediastinal 
nodes 24 h after intravenous administration to the rat [23]. 
Following subcutaneous administration of liposomes, the 
highest reported lymph node uptake was 4.5% of the injected 
dose for the primary node (popliteal) ana I.S% for the sec-
ondary node (iliac) [4]. Using the weight of nodes used above, 
this equates to 375%/g and 13S%/g for the primary and sec-
ondary nodes respectively. The results presented herein for 
PLGA nanospheres are, therefore, far superior to previous 
results obtained with other biodegradable nanospheres. Only 
results obtained with model polystyrene nanospheres have 
produced higher lymph node uptake [2]. 
In conclusion, the results show that it is possible to deliver 
therapeutic and diagnostic agents to the regional lymph nodes 
using biodegradable nanospheres following interstitial admin-
istration. We are presently studying alternative methods to 
label PLGA nanospheres as well as alter animal models dis-
playing pathological states that involve the regional lympha-
tics. 
The distribution of surface modified PLGA nanospheres, 6 h after subcutaneous administration to the rat 
Polymer Injection site Total lymph nodes Liver Blood 
Poloxamer 
401 54.7±9.9 6.6±2.0 2.1 ±0.2 8.8 ± 1.6 
402 64.4 ± 5.1 7.2± 0.8 2.5 ±0.3 9.8 ±2.5 
403 66.7±2.0 9.4 ± 5.7 2.0±0.3 10.1 ±4.0 
407 45.9±4.1 11.3±4.6 8.8 ± 1.9 10.3±0.9 
Poloxamine 
901 Flocculation 
904 69.7±7.2 12.4 ± 2.3 1.9 ± 0.7 4.5±0.8 
908 49.9 ± 5.7 16.8 ± 3.3 5.4 ± 0.6 10.8 ± 2.6 
Data are expressed as % of initial dose (n == 3). 
Recovery 
84.3 ± 15.4 
96.6±1.4 
98.4 ± 6.3 
90.0±3.1 
96.3 ± 7.5 
95.2 ±2.9 
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Fig. 2. Regional lymph node uptake of PLGA nanospheres. 
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